Alpha DNA Investment Management’s Medtronic MDT Stock Holding History

Alpha DNA Investment Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,168	Closed	-$1.77M	–	104
2024 Q4	$1.77M	Buy	22,168 +9,387	+73%	+$813K	0.67%	31
2024 Q3	$1.15M	Sell	12,781 -9,504	-43%	-$800K	0.43%	43
2024 Q2	$1.75M	Sell	22,285 -931	-4%	-$76.3K	0.68%	35
2024 Q1	$2.02M	Sell	23,216 -873	-4%	-$74.5K	0.75%	23
2023 Q4	$1.98M	Buy	24,089 +11,754	+95%	+$896K	0.77%	21
2023 Q3	$967K	Sell	12,335 -9,574	-44%	-$801K	0.4%	50
2023 Q2	$1.93M	Buy	21,909 +10,462	+91%	+$901K	0.64%	27
2023 Q1	$923K	Buy	11,447 +2,263	+25%	+$184K	0.27%	130
2022 Q4	$714K	Buy	9,184 +2,294	+33%	+$186K	0.25%	139
2022 Q3	$556K	Buy	+6,890	New	+$619K	0.46%	99
2021 Q2	–	Sell	-19	Closed	-$2K	–	415
2021 Q1	$2K	Hold	19	–	–	﹤0.01%	569
2020 Q4	$2K	Buy	+19	New	+$2.09K	﹤0.01%	468

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpha DNA Investment Management's MDT Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Medtronic (MDT) in Q1 2025, closing a stake of 22,168 shares — an estimated $1.77M sold.

Alpha DNA Investment Management first reported a position in MDT in Q4 2020 and held it in 12 quarters. The position peaked at $2.02M in Q1 2024. 2,170 funds tracked by Wall St. Rank hold MDT as of Q1 2025.

Alpha DNA Investment Management reported no remaining Medtronic position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 22,168 Medtronic shares in Q1 2025, an estimated $1.77M.
Alpha DNA Investment Management first reported a position in Medtronic in Q4 2020 and held it in 12 quarters.
Alpha DNA Investment Management's Medtronic position peaked at $2.02M in Q1 2024.
2,170 funds tracked by Wall St. Rank held Medtronic as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.